Clinical TrialJun 5, 2026, 04:06 PM
Shattuck Labs to Present Phase 1 SL-325 Clinical Data & Pipeline Update
AI Summary
Shattuck Labs, Inc. announced it will host an investor call and webcast on June 8, 2026, to present comprehensive Phase 1 clinical data for its lead program, SL-325. The presentation will cover safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic, and immunogenicity results. Additionally, the company plans to provide an update on its pipeline of DR3-blocking antibodies for inflammatory and immune-mediated diseases.
Key Highlights
- Shattuck Labs to host an investor call and webcast on Monday, June 8, 2026, at 8:00 a.m. ET.
- The event will present comprehensive Phase 1 clinical data for SL-325.
- Data to include safety, tolerability, pharmacokinetics, receptor occupancy, pharmacodynamic, and immunogenicity results.
- The company will also provide a pipeline update during the event.
- SL-325 is a potential first-in-class DR3 blocking antibody for inflammatory and immune-mediated diseases.
- Presentations will be given by members of Shattuck's management team.
Price Impact
More from STTK